DOSSIERS
Vous trouverez ci-dessous une série d’articles liée à la thématique abordée dans cette section. Ces contenus sont proposés sous la forme de podcasts, d'interviews, de videos, d'infographies,….
PRODUITS
Cette partie regroupe des informations sur nos produits qui peuvent vous être utiles.
Fruzaqla Efficacy
FRESCO-2 was a global, randomized, double-blind, multicenter phase 3 study, evaluating the efficacy and safety of Fruzaqla + best supportive care (BSC) vs. Placebo + BSC.1,2
FRUZAQLA Safety Profile
In FRESCO-2, the majority of adverse events (AEs) with Fruzaqla were manageable and predictable1-3
Fruzaqla Mode of Action
Fruzaqla is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib.1